Compare · BDX vs NVRO
BDX vs NVRO
Side-by-side comparison of Becton Dickinson and Company (BDX) and Nevro Corp. (NVRO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BDX and NVRO operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BDX is the larger of the two at $51.69B, about 24.0x NVRO ($2.15B).
- BDX has hit the wire 10 times in the past 4 weeks while NVRO has been quiet.
- Both have 25 recent analyst ratings on file.
- Company
- Becton Dickinson and Company
- Nevro Corp.
- Price
- -
- -
- Market cap
- $51.69B
- $2.15B
- 1M return
- +19.45%
- -
- 1Y return
- -2.22%
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NYSE
- IPO
- 2014
- News (4w)
- 10
- 0
- Recent ratings
- 25
- 25
Becton Dickinson and Company
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps, dedicated disposables, IV fluids, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products and systems; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for high-throughput single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.
Nevro Corp.
Nevro Corp., a medical device company, provides products for patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain, as well as Senza II and Senza Omnia systems. In addition, the company provides HF10 Therapy, which delivers neuromodulation solutions for treating chronic pain based on available clinical evidence. It sells its products through its direct sales force, and a network of sales agents and independent distributors. The company was incorporated in 2006 and is headquartered in Redwood City, California.
Latest BDX
- EVP, Chief Revenue Officer Feld Michael covered exercise/tax liability with 1,049 shares, decreasing direct ownership by 5% to 19,885 units (SEC Form 4) (for withholding tax)
- BD Appoints Gary Sorsher as Chief Quality Officer; Jeff Silvestri to Retire
- Chairman, CEO and President Polen Thomas E Jr exercised 43,278 shares at a strike of $167.25, returned $7,238,310 worth of shares to the company (39,126 units at $185.00) and sold $768,120 worth of shares (4,152 units at $185.00) as part of a pre-agreed trading plan (SEC Form 4)
- EVP and President, EMEA Goette Roland sold $440,888 worth of shares (2,438 units at $180.84), decreasing direct ownership by 14% to 14,856 units (SEC Form 4)
- BD Accelerates Advanced Tissue Regeneration Strategy with Landmark PREVENT Trial
- SEC Form 4 filed by Director Huffines Robert Luther
- SEC Form 4 filed by Director Byington Carrie L
- SEC Form 10-Q filed by Becton Dickinson and Company
- Becton Dickinson and Company filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- BD Reports Third Quarter Fiscal 2026 Financial Results
Latest NVRO
- SEC Form 15-12G filed by Nevro Corp.
- SEC Form EFFECT filed by Nevro Corp.
- Amendment: SEC Form SCHEDULE 13D/A filed by Nevro Corp.
- Director Mccormick Shawn returned 46,035 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Kosaraju Sridhar returned 46,575 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Grossman D Keith returned 228,552 shares to the company, closing all direct ownership in the company (SEC Form 4)
- SVP, Chief Financial Officer Macleod Roderick H. returned 350,663 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Demane Michael F returned 503,618 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Karros Kirt P returned 17,452 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Oboyle Kevin C returned 43,396 shares to the company, closing all direct ownership in the company (SEC Form 4)